Conference Description:

With new & emerging targets and drug candidates in immuno-oncology, key opinion leaders from pharmaceutical & biotech companies as well as academic & research organisations will be presenting on innovative approaches & methods for target identification & validation, such as AI-based strategies, novel checkpoint inhibitors and latest developments & case studies in cellular therapies : TILs, gamma deltas, myeloid cells.

Expand your knowledge & discuss future priorities in:
- Emerging Technologies, Strategies & Methods for Novel Targets & Target Validation in Immuno-Oncology
- Novel Cell Types to Develop Effective IO Therapies



Meet key decision markers representing large pharma & biotech companies:
- Kris Clark, Grey Wolf Therapeutics
- Stefano Sammicheli, Ichnos Sciences
- Jorg Rippmann, Boehringer Ingelheim
- Gregory Vladimer, Exscientia
- Nisit Khandelwal, iOmx Therapeutics
- Cecile Bauche, Alaya.bio
& much more!

View the agenda:https://www.oxfordglobal.co.uk/im muno-targets-cells/agenda/?utm_source=wc c&utm_medium=eventlisting&utm_campaign=i mmuno&utm_content=tacell2023


Co-located with Biomarkers Europe 2023 and Precision Oncology Europe 2023, attendees will receive access to all three events. For more information contact [email protected]